RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older

JAMA. 2024 Oct 1;332(13):1105-1107. doi: 10.1001/jama.2024.15775.
No abstract available

Plain language summary

This study evaluates the effectiveness of the respiratory syncytial virus vaccine against hospitalization for acute respiratory illness among US adults aged 60 years and older.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Male
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus Infections* / immunology
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus Vaccines* / administration & dosage
  • Respiratory Syncytial Virus Vaccines* / immunology
  • United States / epidemiology
  • Vaccine Efficacy* / statistics & numerical data

Substances

  • Respiratory Syncytial Virus Vaccines